Cargando…

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase

BACKGROUND: Some cancers have been shown to lack expression of argininosuccinate synthetase (ASS), an enzyme required for the synthesis of arginine and a possible biomarker of sensitivity to arginine deprivation. Arginine deiminase (ADI) is a microbial enzyme capable of efficiently depleting periphe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, M P, Jungbluth, A A, Wu, B-W, Bomalaski, J, Old, L J, Ritter, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261683/ https://www.ncbi.nlm.nih.gov/pubmed/22134507 http://dx.doi.org/10.1038/bjc.2011.524

Ejemplares similares

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis
por: Delage, B, et al.
Publicado: (2012)

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
por: Beddowes, Emma, et al.
Publicado: (2017)

RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
por: Wu, Fe-Lin Lin, et al.
Publicado: (2011)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy
por: McAlpine, Jennifer A, et al.
Publicado: (2014)

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma
por: Syed, N, et al.
Publicado: (2013)

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling
por: Liu, Jiangbo, et al.
Publicado: (2014)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
por: Park, I-S, et al.
Publicado: (2003)

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
por: Cheon, Dong‐Joo, et al.
Publicado: (2014)

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
por: Chang, Kwang-Yu, et al.
Publicado: (2021)

Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines
por: Roeksomtawin, Somphon, et al.
Publicado: (2018)

Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism
por: Zhang, Yiming, et al.
Publicado: (2022)

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients
por: Tsai, Hui-Jen, et al.
Publicado: (2017)

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)
por: Burrows, Natalie, et al.
Publicado: (2016)

Epithelial argininosuccinate synthetase is dispensable for intestinal regeneration and tumorigenesis
por: van der Meer, Jonathan H. M., et al.
Publicado: (2021)

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines
por: Shan, Yan-Shen, et al.
Publicado: (2015)

The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma
por: Thongkum, Angkana, et al.
Publicado: (2017)

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
por: Yang, T-S, et al.
Publicado: (2010)

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression
por: Kim, Stephanie S., et al.
Publicado: (2020)

Combination therapy with PEG-IFN-α and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53
por: Hagiwara, S, et al.
Publicado: (2007)

C20orf20 (MRG-binding protein) as a potential therapeutic target for colorectal cancer
por: Yamaguchi, K, et al.
Publicado: (2010)

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
por: Przystal, Justyna Magdalena, et al.
Publicado: (2018)

Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
por: Overman, M J, et al.
Publicado: (2010)

Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
por: Deckert, P M, et al.
Publicado: (2003)

Treatment decisions and survival for people with small-cell lung cancer
por: Powell, H A, et al.
Publicado: (2014)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action
por: Wang, W, et al.
Publicado: (2008)

A transgenic approach to study argininosuccinate synthetase gene expression
por: Shiue, Shih-Chang, et al.
Publicado: (2014)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Irreversible electroporation on the small intestine
por: Phillips, M A, et al.
Publicado: (2012)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore
por: Zhang, H, et al.
Publicado: (2009)

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
por: Lamont, F R, et al.
Publicado: (2011)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Impaired TNFα-induced A20 expression in E1A/Ras-transformed cells
por: Huang, H-L, et al.
Publicado: (2009)

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
por: Imai, K, et al.
Publicado: (2011)

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
por: D'Incecco, A, et al.
Publicado: (2015)

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
por: Canner, J A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_j5cpoujtpk5lb0tlntoosq0qdh